Cystic Fibrosis

🧠 Standard of Care

Cystic Fibrosis (CF) is a genetic disorder caused by mutations in the CFTR gene, leading to the production of thick, sticky mucus in the lungs, pancreas, and other organs. Care is multi-disciplinary, requiring strict daily routines.

• Multidisciplinary Care Centers: Regular visits with pulmonologists, respiratory therapists, dietitians, and social workers.
• Nutritional Support: Because CF affects the pancreas, most patients require Pancreatic Enzyme Replacement Therapy (PERT) with meals, along with a high-calorie, high-fat diet and fat-soluble vitamin supplements.
• Pulmonary Function Testing (PFT): Routine spirometry to monitor FEV1 (Forced Expiratory Volume) to track lung disease progression.

🫁 Airway Clearance & Infection Control

Keeping the lungs clear of mucus and bacteria is a daily battle for individuals with CF.

Airway Clearance Techniques (ACTs)

Patients use vibrating vests (High-Frequency Chest Wall Oscillation), positive expiratory pressure (PEP) devices, or manual chest physical therapy to loosen mucus. This is typically done twice a day, or more frequently during exacerbations.

Inhaled Medications

Before ACTs, patients often use inhaled bronchodilators to open airways, followed by mucolytics (like hypertonic saline or dornase alfa) to thin the mucus, making it easier to cough up.

Antibiotic Therapy

Inhaled antibiotics (like tobramycin or aztreonam) are frequently cycled to suppress chronic lung infections, specifically *Pseudomonas aeruginosa*.

💊 CFTR Modulators

While traditional treatments manage symptoms, CFTR modulators address the underlying defect in the CFTR protein, representing a paradigm shift in CF care.

• Trikafta (elexacaftor/tezacaftor/ivacaftor): Approved for patients with at least one F508del mutation (the most common CF mutation), representing ~90% of the CF population. It significantly improves lung function and quality of life.
• Kalydeco (ivacaftor): Used for specific "gating" mutations, helping the defective CFTR channel stay open longer to improve salt and water flow.
• Orkambi and Symdeko: Earlier generation modulators used for specific genetic profiles, often in patients with two copies of the F508del mutation.

🔬 Active Clinical Trials

Despite the success of modulators, research continues for the 10% of patients who do not benefit from them, as well as efforts to improve long-term outcomes for all. Here are some live trials:

• NCT05200429 (University of British Columbia): The Can-IMPACT CF study, an observational trial evaluating the long-term impact of CFTR modulators on the health and quality of life of people with CF.
• NCT06132048 (Ad scientiam): A usability validation of the MuCopilot Mobile Application, a digital health tool designed for the unsupervised objective assessment of Cystic Fibrosis symptoms.

🧬 Genetic Testing and Newborn Screening

Early diagnosis is crucial for mitigating lung damage and ensuring normal growth trajectories in infants.

• Newborn Screening: In the US and many other countries, all newborns are screened for CF via a blood test that checks for high levels of immunoreactive trypsinogen (IRT). If IRT is high, DNA testing for common CFTR mutations is performed.
• Sweat Test: The gold standard for confirming a CF diagnosis. It measures the amount of chloride in the sweat—people with CF have higher than normal chloride levels.
• Carrier Testing: Because CF is autosomal recessive, genetic testing is available for prospective parents to determine if they carry a CFTR mutation.

❓ Patient FAQ

Q: Is Cystic Fibrosis curable?
A: Currently, there is no cure for CF. However, recent advancements, particularly CFTR modulators, have dramatically increased life expectancy and quality of life.

Q: How do people get Cystic Fibrosis?
A: CF is an autosomal recessive genetic disease. A person must inherit two copies of the defective CF gene—one from each parent—to have the disease. Carriers (one copy) do not have symptoms.

Q: Why do people with CF need to stay away from each other?
A: Individuals with CF are highly susceptible to severe lung infections and can easily pass dangerous bacteria (like *Burkholderia cepacia*) to each other. Strict infection control guidelines recommend they maintain a distance of at least 6 feet from one another.